Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Asthma - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 110+ companies and 125+ drugs in Asthma Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In-depth Commercial Assessment: Asthma Collaboration Analysis by Companies
The report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Asthma Competitive Landscape
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Asthma Report Assessment
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
- How many companies are developing Asthma drugs?
- How many Asthma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Asthma and their status?
- What are the key designations that have been granted to the emerging and approved drugs?
Key Players
- Areteia Therapeutics
- Celltrion
- GlaxoSmithKline
- Connect Biopharma
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co.
- Chia Tai Tianqing Pharmaceutical Group
- Aldeyra Therapeutics, Inc.
- Trio Medicines
- AstraZeneca
- Janssen Research & Development
- Tetherex Pharmaceuticals Corporation
- Palobiofarma SL
- Sanofi
- RAPT Therapeutics
- Kashiv BioSciences
- Archivel Farma
- TFF Pharmaceuticals
- Evelo Biosciences, Inc.
- Landos Biopharma
- Adial Pharmaceuticals
- Holth Therapeutics
- Lanier Biotherapeutics
- Omega Therapeutics
- Transpire Bio
- DNARx
- Argenx
- MyMD Pharmaceuticals
- Ventyx Biosciences
- Kither
- Enterprise Therapeutics
Key Products
- Dexpramipexole
- CT-P39
- GSK3511294
- CBP-201
- SHR-1905
- SHR1703
- TQC2731
- ADX-629
- TR4
- MEDI 3506
- Lumicitabine
- SelK2
- PBF-680
- Rilzabrutinib
- RPT 193
- ADL-018
- RUTI
- Voriconazole Inhalation Powder
- EDP1867
- LABP-73
- PNV-5032
- HT004
- ABM125
- Research Program: CXCL 1-8-targeting OEC
- Research program: DPI Asthma
- Mepolizumab biosimilar
- ARGX-118
- MYMD-1
- Research programme: interleukin 4 receptor alpha antagonists
- Research Program
- Mucoregulatory Therapies
For more information about this report visit https://www.researchandmarkets.com/r/eaioxh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
